Related Experiment Videos
Patients' profiles in end stage coronary artery disease. Indications for treatment with transmyocardial laser
R C Funck1, L Rybinski, H König
1Zentrum Innere Medizin-Schwerpunkt Kardiologie, Philipps-Universität Marburg.
Insights
Transmyocardial laser revascularization (TMLR) offers a treatment option for patients with refractory coronary artery disease (CAD). This study evaluated TMLR in 128 patients with advanced CAD, demonstrating its application in complex cases.
Area of Science:
- Cardiology
- Cardiovascular Surgery
- Interventional Cardiology
Background:
- A subset of patients with coronary artery disease (CAD) exhibits refractoriness to existing therapeutic interventions.
- These patients often present with a history of multiple revascularization procedures, severe symptoms, and impaired left ventricular function.
Purpose of the Study:
- To evaluate the application and outcomes of transmyocardial laser revascularization (TMLR) in patients with refractory coronary artery disease.
- To analyze the characteristics of patients undergoing TMLR, either as a standalone procedure or in conjunction with coronary artery bypass grafting.
Main Methods:
- Retrospective analysis of 128 patients who underwent TMLR between [Start Date] and [End Date].
- Detailed review of patient demographics, medical history, previous interventions (coronary artery bypass surgery, percutaneous transluminal coronary angioplasty), symptom severity (Canadian Cardiovascular Society and New York Heart Association classifications), left ventricular ejection fraction, and medical therapy.
- Preoperative assessment of myocardial viability, inducible ischemia, and coronary morphology guided treatment decisions.
Main Results:
- Patients had a mean age of 62.2 years, with a high prevalence of prior bypass surgery (89.9%) and percutaneous transluminal coronary angioplasty (44.5%).
- Over 90% had a history of myocardial infarction and presented with severe angina (CCS Class III/IV) and heart failure (NYHA Class III/IV).
- Left ventricular ejection fraction averaged 49.5%, with patients on intensive anti-ischemic medical therapy.
Conclusions:
- Transmyocardial laser revascularization (TMLR) is a viable option for select patients with severe, refractory coronary artery disease (CAD) who have failed conventional therapies.
- Careful preoperative assessment of myocardial viability and patient risk factors is crucial for optimizing the selection of TMLR and/or concomitant surgical revascularization.
Abstract:
There is a subgroup of patients with coronary artery disease who are refractory to the therapeutical methods so far applied. We report on 128 patients who fulfill this definition and have therefore undergone pure transmyocardial laser revascularisation (TMLR) or transmyocardial laser revascularisation in combination with coronary bypass surgery at our institution. The patients can be characterized by a long history of coronary artery disease with multiple revascularizing procedures, e.g. bypass surgery or percutaneous transluminal coronary angioplasty (PTCA), pronounced symptoms of coronary artery disease and chronic heart failure in the presence of markedly reduced left ventricular ejection fractions and intense antiischemic medical therapy. The patients were 62.2 +/- 9.8 (SD) years of age, in 89.9% of them at least one bypass operation and in 44.5% up to more than three percutaneous transluminal coronary angioplasties (PTCAs) had been performed prior to TMLR. There was a history of myocardial infarction in 90.7% of patients and 89.8% were in the Canadian Cardiovascular Society (CCS) classes III or IV and 94.5% of them were in the NYHA classes III or IV. The left ventricular ejection fraction was 49.5 +/- 16.4% and all of the patients were under intense antiischemic medical treatment which included nitrates or molsidomine in 96.9%, beta blockers in 53.1%, angiotensin converting enzyme inhibitors (ACE inhibitors) in 44.5%, digitalis in 22.7% and diuretics in 52.3% of patients. The preoperative data on myocardial viability, inducible ischemia and coronary morphology provided important clinical information for the decision, which revascularizing method would be the most appropriate for each vessel or myocardial region. This had to be weighed against the patient's operative risk, which is predominantly determined by the left ventricular ejection fraction, the arteriosclerotic involvement of the remaining vascular system and concomitant diseases, particularly of pulmonary origin.